Proteomics in chronic wound research: Potentials in healing and health

Proteomics - Clinical Applications

Volumn 4, Issue 2, 2010, Pages 204-214

  Broadbent, James ^a   Walsh, Terry ^a   Upton, Zee ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Chronic wound; Diabetes; Leg ulcer; Proteomic application

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; ELASTASE; EPIDERMAL GROWTH FACTOR; EPITHELIAL GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR; INFLIXIMAB; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN;

CHRONIC WOUND; CLINICAL ASSESSMENT; DECUBITUS; DIABETIC FOOT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEG ULCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; QUALITY OF LIFE; REVIEW; SCLERODERMA; SKIN ULCER; TREATMENT OUTCOME; WESTERN BLOTTING; WOUND CARE; WOUND FLUID; WOUND HEALING;

BIOLOGICAL MARKERS; HEALTH; HUMANS; PROGNOSIS; PROTEOMICS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 77951927515     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900152     Document Type: Review

References (119)

1. Wysocki, A.B., Wound fluids and the pathogenesis of chronic wounds. J. Wound Ostomy Continence Nurs. 1996, 23, 283-290.
2. Branski, L.K., Gauglitz, G.G., Herndon, D.N., Jeschke, M.G., A review of gene and stem cell therapy in cutaneous wound healing. Burns 2009, 35, 171-180.
3. Sussman, C., Pain doesn't have to be a part of wound care. Ostomy Wound Manage. 2003, 49, 10-12.
4. Posnett, J., Franks, P.J., The burden of chronic wounds in the UK. Nurs. Times 2008, 104, 44-45.
5. Walshe, C., Living with a venous leg ulcer: a descriptive study of patients' experiences. J. Adv. Nurs. 1995, 22, 1092-1100.
6. Anand, S.C., Dean, C., Nettleton, R., Praburaj, D.V., Health-related quality of life tools for venous-ulcerated patients. Br. J. Nurs. 2003, 12, 48-59.
7. Campbell, L.V., Graham, A.R., Kidd, R.M., Molloy, H.F. et al., The lower limb in people with diabetes position statement of the Australian Diabetes Society. Med. J. Aust. 2000, 173, 369-372.
8. Abd-El-Aleem, S.A., Ferguson, M.W., Appleton, I., Kairsingh, S. et al., Expression of nitric oxide synthase isoforms and arginase in normal human skin and chronic venous leg ulcers. J. Pathol. 2000, 191, 434-442.
9. Harris, I.R., Yee, K.C., Walters, C.E., Cunliffe, W.J. et al., Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp. Dermatol. 1995, 4, 342-349.
10. Nwomeh, B.C., Liang, H.X., Cohen, I.K., Yager, D.R., MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J. Surg. Res. 1999, 81, 189-195.
11. Wysocki, A.B., Grinnell, F., Fibronectin profiles in normal and chronic wound fluid. Lab. Invest. 1990, 63, 825-831.
12. Abbade, L.P., Lastoria, S., Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int. J. Dermatol. 2005, 44, 449-456.
13. Sacks, D., Bakal, C.W., Beatty, P.T., Becker, G.J. et al., Position statement on the use of the ankle brachial index in the evaluation of patients with peripheral vascular disease. A consensus statement developed by the Standards Division of the Society of Interventional Radiology. J. Vasc. Interv. Radiol. 2003, 14, S389.
14. Porter, J.M., Moneta, G.L., Reporting standards in venous disease: an update International Consensus Committee on Chronic Venous Disease. J. Vasc. Surg. 1995, 21, 635-645.
15. Charles, C.A., Tomic-Canic, M., Vincek, V., Nassiri, M. et al., A gene signature of nonhealing venous ulcers: potential diagnostic markers. J. Am. Acad. Dermatol. 2008, 59, 758-771.
16. Rasmussen, L.H., Jensen, L.T., Avnstorp, C., Karlsmark, T. et al., Collagen types I and III propeptides as markers of healing in chronic leg ulcers. A noninvasive method for the determination of procollagen propeptides in wound fluid - influence of growth hormone. Ann. Surg. 1992, 216, 684-691.
17. Shukla, V.K., Shukla, D., Tiwary, S.K., Agrawal, S., Rastogi, A., Evaluation of pH measurement as a method of wound assessment. J. Wound Care 2007, 16, 291-294.
18. Yager, D.R., Kulina, R.A., Gilman, L.A., Wound fluids: A window into the wound environment? Int. J. Low Extrem. Wound 2007, 6, 262-272.
19. Partsch, H., Compression therapy of venous ulcers. Curr. Probl. Dermatol. 1999, 27, 130-140.
20. Robson, M.C., Cooper, D.M., Aslam, R., Gould, L.J. et al., Guidelines for the prevention of venous ulcers. Wound Repair Regen. 2008, 16, 147-150.
21. Hopf, H.W., Ueno, C., Aslam, R., Dardik, A. et al., Guidelines for the prevention of lower extremity arterial ulcers. Wound Repair Regen. 2008, 16, 175-188.
22. Kranke, P., Bennett, M., Roeckl-Wiedmann, I., Debus, S., Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst. Rev. 2004, 4, 1-38, CD004123.
23. Stechmiller, J.K., Cowan, L., Whitney, J.D., Phillips, L. et al., Guidelines for the prevention of pressure ulcers. Wound Repair Regen. 2008, 16, 151-168.
24. Wood, M.K., Davies, D.M., Use of split-skin grafting in the treatment of chronic leg ulcers. Ann. R Coll. Surg. Engl. 1995, 77, 222-223.
25. Cowin, A.J., Hatzirodos, N., Rigden, J., Fitridge, R., Belford, D.A., Etanercept decreases tumor necrosis factoralpha activity in chronic wound fluid. Wound Repair Regen. 2006, 14, 421-426.
26. Wieman, T.J., Smiell, J.M., Su, Y., Efficacy and safety of a topical gel formulation of recombinant human plateletderived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diab. Care 1998, 21, 822-827.
27. Embil, J.M., Papp, K., Sibbald, G., Tousignant, J. et al., Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen. 2000, 8, 162-168.
28. Smiell, J.M., Wieman, T.J., Steed, D.L., Perry, B.H. et al., Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999, 7, 335-346.
29. Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H., Tomic-Canic, M., Growth factors and cytokines in wound healing. Wound Repair Regen. 2008, 16, 585-601.
30. Upton, Z., Cuttle, L., Noble, A., Kempf, M. et al., Vitronectin: growth factor complexes hold potential as a wound therapy approach. J. Invest. Dermatol. 2008, 128, 1535-1544.
31. Fernandez-Montequin, J.I., Betancourt, B.Y., Leyva-Gonzalez, G., Mola, E.L. et al., Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int. Wound J. 2009, 6, 67-72.
32. Yamanaka, K., Inaba, T., Nomura, E., Hurwitz, D. et al., Basic fibroblast growth factor treatment for skin ulcerations in scleroderma. Cutis 2005, 76, 373-376.
33. Vuerstaek, J.D., Vainas, T., Wuite, J., Nelemans, P. et al., State-of-the-art treatment of chronic leg ulcers: a randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. J. Vasc. Surg. 2006, 44, 1029-1037; discussion 1038.
34. Banks, P.G., Ho, C.H., A novel topical oxygen treatment for chronic and difficult-to-heal wounds: case studies. J. Spinal Cord. Med. 2008, 31, 297-301.
35. Cole, P.S., Quisberg, J., Melin, M.M., Adjuvant use of acoustic pressure wound therapy for treatment of chronic wounds: a retrospective analysis. J. Wound Ostomy. Contin. Nurs. 2009, 36, 171-177.
36. Durovic, A., Maric, D., Brdareski, Z., Jevtic, M., Durdevic, S., The effects of polarized light therapy in pressure ulcer healing. Vojnosanit. Pregl. 2008, 65, 906-912.
37. Ly, M., Poole-Warren, L., Acceleration of wound healing using electric fields: time for a stimulating discussion. Wound Prac. Res. 2008, 16, 138-151.
38. Moore, K., Huddleston, E., Stacey, M.C., Harding, K.G., Venous leg ulcers - the search for a prognostic indicator. Int. Wound J. 2007, 4, 163-172.
39. Ratliff, C.R., Rodeheaver, G.T., Use of the PUSH tool to measure venous ulcer healing. Ostomy. Wound Manage. 2005, 51, 58-60, 62-53.
40. Armstrong, D.G., Lavery, L.A., Harkless, L.B., Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diab. Care 1998, 21, 855-859.
41. Beckert, S., Pietsch, A.M., Kuper, M., Wicke, C. et al., M.A.I.D.: a prognostic score estimating probability of healing in chronic lower extremity wounds. Ann. Surg. 2009, 249, 677-681.
42. Rayment, E.A., Upton, Z., Finding the culprit: a review of the influences of proteases on the chronic wound environment. Int. J. Low Extrem. Wound 2009, 8, 19-27.
43. Tarlton, J.F., Bailey, A.J., Crawford, E., Jones, D. et al., Prognostic value of markers of collagen remodeling in venous ulcers. Wound Repair Regen. 1999, 7, 347-355.
44. Drinkwater, S.L., Smith, A., Burnand, K.G., What can wound fluids tell us about the venous ulcer microenvironment? Int. J. Low Extrem. Wound 2002, 1, 184-190.
45. Staiano-Coico, L., Higgins, P.J., Schwartz, S.B., Zimm, A.J., Goncalves, J., Wound fluids: a reflection of the state of healing. Ostomy Wound Manage. 2000, 46, 85S-93S; quiz 94S-95S.
46. Grinnell, F., Zhu, M., Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J. Invest. Dermatol. 1996, 106, 335-341.
47. De Mattei, M., Ongaro, A., Magaldi, S., Gemmati, D. et al., Time- and dose-dependent effects of chronic wound fluid on human adult dermal fibroblasts. Dermatol. Surg. 2008, 34, 347-356.
48. He, C., Hughes, M.A., Cherry, G.W., Arnold, F., Effects of chronic wound fluid on the bioactivity of platelet-derived growth factor in serum-free medium and its direct effect on fibroblast growth. Wound Repair Regen. 1999, 7, 97-105.
49. Mendez, M.V., Raffetto, J.D., Phillips, T., Menzoian, J.O., Park, H.Y., The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: a potential mechanism for senescence in venous ulcers. J. Vasc. Surg. 1999, 30, 734-743.
50. Phillips, T.J., al-Amoudi, H.O., Leverkus, M., Park, H.Y., Effect of chronic wound fluid on fibroblasts. J. Wound Care 1998, 7, 527-532.
51. Raffetto, J.D., Mendez, M.V., Marien, B.J., Byers, H.R. et al., Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J. Vasc. Surg. 2001, 33, 1233-1241.
52. Seah, C.C., Phillips, T.J., Howard, C.E., Panova, I.P. et al., Chronic wound fluid suppresses proliferation of dermal fibroblasts through a Ras-mediated signaling pathway. J. Invest. Dermatol. 2005, 124, 466-474.
53. Ulrich, D., Lichtenegger, F., Unglaub, F., Smeets, R., Pallua, N., Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast. Reconstr. Surg. 2005, 116, 539-545.
54. Weckroth, M., Vaheri, A., Myohanen, H., Tukiainen, E., Siren, V., Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinasetype plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Wound Repair Regen. 2001, 9, 314-322.
55. Rao, C.N., Ladin, D.A., Liu, Y.Y., Chilukuri, K. et al., Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J. Invest. Dermatol. 1995, 105, 572-578.
56. Trengove, N.J., Langton, S.R., Stacey, M.C., Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers. Wound Repair Regen. 1996, 4, 234-239.
57. Wagner, S., Coerper, S., Fricke, J., Hunt, T.K. et al., Comparison of inflammatory and systemic sources of growth factors in acute and chronic human wounds. Wound Repair Regen. 2003, 11, 253-260.
58. James, T.J., Hughes, M.A., Cherry, G.W., Taylor, R.P., Evidence of oxidative stress in chronic venous ulcers. Wound Repair Regen. 2003, 11, 172-176.
59. Schmidtchen, A., Degradation of antiproteinases, complement and fibronectin in chronic leg ulcers. Acta Derm. Venereol. 2000, 80, 179-184.
60. Grinnell, F., Ho, C.H., Wysocki, A., Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J. Invest. Dermatol. 1992, 98, 410-416.
61. Trengove, N.J., Stacey, M.C., MacAuley, S., Bennett, N. et al., Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999, 7, 442-452.
62. Wysocki, A.B., Kusakabe, A.O., Chang, S., Tuan, T.L., Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Repair Regen. 1999, 7, 154-165.
63. Yager, D.R., Zhang, L.Y., Liang, H.X., Diegelmann, R.F., Cohen, I.K., Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J. Invest. Dermatol. 1996, 107, 743-748.
64. Fivenson, D.P., Faria, D.T., Nickoloff, B.J., Poverini, P.J. et al., Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen. 1997, 5, 310-322.
65. Dalton, S.J., Whiting, C.V., Bailey, J.R., Mitchell, D.C., Tarlton, J.F., Mechanisms of chronic skin ulceration linking lactate, transforming growth factor-beta, vascular endothelial growth factor, collagen remodeling, collagen stability, and defective angiogenesis. J. Invest. Dermatol. 2007, 127, 958-968.
66. Galkowska, H., Olszewski, W.L., Wojewodzka, U., Expression of natural antimicrobial peptide beta-defensin-2 and Langerhans cell accumulation in epidermis from human non-healing leg ulcers. Folia Histochem. Cytobiol. 2005, 43, 133-136.
67. Luk, P.P., Sinha, S.N., Lord, R., Upregulation of inducible nitric oxide synthase (iNOS) expression in faster-healing chronic leg ulcers. J. Wound Care 2005, 14, 373-375, 378-381.
68. Simonsen, L., Holstein, P., Larsen, K., Bulow, J., Glucose metabolism in chronic diabetic foot ulcers measured in vivo using microdialysis. Clin. Physiol. 1998, 18, 355-359.
69. Fernandez, M.L., Broadbent, J.A., Shooter, G.K., Malda, J., Upton, Z., Development of an enhanced proteomic method to detect prognostic and diagnostic markers of healing in chronic wound fluid. Br. J. Dermatol. 2008, 158, 281-290.
70. Smith, E., Hoffman, R., Multiple fragments related to angiostatin and endostatin in fluid from venous leg ulcers. Wound Repair Regen. 2005, 13, 148-157.
71. Cravatt, B.F., Simon, G.M., Yates, J.R., III, The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450, 991-1000.
72. Moseley, R., Hilton, J.R., Waddington, R.J., Harding, K.G. et al., Comparison of oxidative stress biomarker profiles between acute and chronic wound environments. Wound Repair Regen. 2004, 12, 419-429.
73. Edwards, J.V., Bopp, A.F., Batiste, S., Ullah, A.J. et al., Inhibition of elastase by a synthetic cotton-bound serine protease inhibitor: in vitro kinetics and inhibitor release. Wound Repair Regen. 1999, 7, 106-118.
74. Hoffman, R., Starkey, S., Coad, J., Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. J. Invest. Dermatol. 1998, 111, 1140-1144.
75. Latijnhouwers, M.A., Bergers, M., Veenhuis, R.T., Beekman, B. et al., Tenascin-C degradation in chronic wounds is dependent on serine proteinase activity. Arch. Dermatol. Res. 1998, 290, 490-496.
76. Weckroth, M., Vaheri, A., Lauharanta, J., Sorsa, T., Konttinen, Y.T., Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J. Invest. Dermatol. 1996, 106, 1119-1124.
77. Palolahti, M., Lauharanta, J., Stephens, R.W., Kuusela, P., Vaheri, A., Proteolytic activity in leg ulcer exudate. Exp. Dermatol. 1993, 2, 29-37.
78. Stanley, C.M., Wang, Y., Pal, S., Klebe, R.J. et al., Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J. Periodontol. 2008, 79, 861-875.
79. Beidler, S.K., Douillet, C.D., Berndt, D.F., Keagy, B.A. et al., Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair Regen. 2008, 16, 642-648.
80. Bullen, E.C., Longaker, M.T., Updike, D.L., Benton, R. et al., Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J. Invest. Dermatol. 1995, 104, 236-240.
81. Gohel, M.S., Windhaber, R.A., Tarlton, J.F., Whyman, M.R., Poskitt, K.R., The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J. Vasc. Surg. 2008, 48, 1272-1277.
82. Mwaura, B., Mahendran, B., Hynes, N., Defreitas, D. et al., The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur. J. Vasc. Endovasc. Surg. 2006, 31, 306-310.
83. Ladwig, G.P., Robson, M.C., Liu, R., Kuhn, M.A. et al., Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002, 10, 26-37.
84. Rayment, E.A., Upton, Z., Shooter, G.K., Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br. J. Dermatol. 2008, 158, 951-961.
85. Cullen, B., Smith, R., McCulloch, E., Silcock, D., Morrison, L., Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002, 10, 16-25.
86. Rayment, E.A., Dargaville, T.R., Shooter, G.K., George, G.A., Upton, Z., Attenuation of protease activity in chronic wound fluid with bisphosphonate-functionalised hydrogels. Biomaterials 2008, 29, 1785-1795.
87. Liu, Y., Min, D., Bolton, T., Nube, V. et al., Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diab. Care 2009, 32, 117-119.
88. Eming, S.A., Kaufmann, J., Lohrer, R., Krieg, T., [Chronic wounds. Novel approaches in research and therapy]. Hautarzt 2007, 58, 939-944.
89. Lobmann, R., Ambrosch, A., Schultz, G., Waldmann, K. et al., Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002, 45, 1011-1016.
90. Norgauer, J., Hildenbrand, T., Idzko, M., Panther, E. et al., Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br. J. Dermatol. 2002, 147, 1180-1186.
91. Brem, H., Golinko, M.S., Stojadinovic, O., Kodra, A. et al., Primary cultured fibroblasts derived from patients with chronic wounds: a methodology to produce human cell lines and test putative growth factor therapy such as GMCSF. J. Transl. Med. 2008, 6, 75.
92. Barone, E.J., Yager, D.R., Pozez, A.L., Olutoye, O.O. et al., Interleukin-1alpha and collagenase activity are elevated in chronic wounds. Plast. Reconstr. Surg. 1998, 102, 1023-1027; discussion 1028-1029.
93. Beidler, S.K., Douillet, C.D., Berndt, D.F., Keagy, B.A. et al., Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J. Vasc. Surg. 2009, 49, 1013-1020.
94. Charles, C.A., Romanelli, P., Martinez, Z.B., Ma, F. et al., Tumor necrosis factor-alfa in nonhealing venous leg ulcers. J. Am. Acad. Dermatol. 2009, 60, 951-955.
95. Trengove, N.J., Bielefeldt-Ohmann, H., Stacey, M.C., Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000, 8, 13-25.
96. Streit, M., Beleznay, Z., Braathen, L.R., Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int. Wound J. 2006, 3, 171-179.
97. Lauer, G., Sollberg, S., Cole, M., Flamme, I. et al., Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 2000, 115, 12-18.
98. Galkowska, H., Wojewodzka, U., Olszewski, W.L., Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen. 2006, 14, 558-565.
99. Nayeri, F., Olsson, H., Peterson, C., Sundqvist, T., Hepatocyte growth factor; expression, concentration and biological activity in chronic leg ulcers. J. Dermatol. Sci. 2005, 37, 75-85.
100. Cowin, A.J., Hatzirodos, N., Holding, C.A., Dunaiski, V. et al., Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J. Invest. Dermatol. 2001, 117, 1282-1289.
101. Jude, E.B., Boulton, A.J., Ferguson, M.W., Appleton, I., The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modu-latory effects by transforming growth factor beta 1. Diabetologia 1999, 42, 748-757.
102. Jude, E.B., Blakytny, R., Bulmer, J., Boulton, A.J., Ferguson, M.W., Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet. Med. 2002, 19, 440-447.
103. Blakytny, R., Jude, E.B., Martin Gibson, J., Boulton, A.J., Ferguson, M.W., Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J. Pathol. 2000, 190, 589-594.
104. Takenaka, H., Yasuno, H., Kishimoto, S., Immunolocalization of fibroblast growth factor receptors in normal and wounded human skin. Arch. Dermatol. Res. 2002, 294, 331-338.
105. Omenn, G.S., States, D.J., Adamski, M., Blackwell, T.W. et al., Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.
106. Grey, J.E., Enoch, S., Harding, K.G., Wound assessment. Br. Med. J. 2006, 332, 285-288.
107. Wolcott, R.D., Rhoads, D.D., Dowd, S.E., Biofilms and chronic wound inflammation. J. Wound Care 2008, 17, 333-341.
108. Schmidtchen, A., Chronic ulcers: a method for sampling and analysis of wound fluid. Acta. Derm. Venereol. 1999, 79, 291-295.
109. Clough, G., Noble, M., Microdialysis - a model for studying chronic wounds. Int. J. Low Extrem. Wound 2003, 2, 233-239.
110. Dealey, C., Cameron, J., Arrowsmith, M., A study comparing two objective methods of quantifying the production of wound exudate. J. Wound Care 2006, 15, 149-153.
111. Boschetti, E., Righetti, P.G., The ProteoMiner in the proteomic arena: a non-depleting tool for discovering lowabundance species. J. Proteomics 2008, 71, 255-264.
112. Bjorhall, K., Miliotis, T., Davidsson, P., Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5, 307-317.
113. Kim, Y.S., Son, O.L., Lee, J.Y., Kim, S.H. et al., Lectin precipitation using phytohemagglutinin-L(4) coupled to avidin-agarose for serological biomarker discovery in colorectal cancer. Proteomics 2008, 8, 3229-3235.
114. Horth, P., Miller, C.A., Preckel, T., Wenz, C., Efficient fractionation and improved protein identification by peptide OFFGEL electrophoresis. Mol. Cell Proteomics 2006, 5, 1968-1974.
115. Saerens, D., Ghassabeh, G.H., Muyldermans, S., Antibody technology in proteomics. Brief Funct. Genomic Proteomic 2008, 7, 275-282.
116. Borrebaeck, C.A., Wingren, C., High-throughput proteomics using antibody microarrays: an update. Expert Rev. Mol. Diagn. 2007, 7, 673-686.
117. Anderson, L., Hunter, C.L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 2006, 5, 573-588.
118. Kuzyk, M.A., Smith, D., Yang, J., Cross, T.J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 2009, 8, 1860-1877.
119. Wiese, S., Reidegeld, K.A., Meyer, H.E., Warscheid, B., Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7, 340-350.